This statistic shows the number of registrations of newly diagnosed cases of colon cancer in England in 2022, by age group and gender. The group most affected by colon cancer was men aged 75 to 79 years, with *** thousand cases registered. It should, of course, be noted that the number of people in England in each age group varies and is therefore not necessarily a reflection of susceptibility to colon cancer.

In 2022, 55.8 males and 44.3 females per 100,000 population in England were registered as newly diagnosed with colon cancer. The rate of both females and males registered as newly diagnosed with colon cancer considerably decreased from the previous year. This statistic shows the rate of newly diagnosed cases of colon cancer per 100,000 population in England from 1995 to 2022, by gender.

Death rate has been age-adjusted to the 2000 U.S. standard population. Single-year data are only available for Los Angeles County overall, Service Planning Areas, Supervisorial Districts, City of Los Angeles overall, and City of Los Angeles Council Districts.Being physically active and eating a diet that is rich in fruits, vegetables, lean meats, and fiber can reduce the risk of colon cancer. Promoting healthy food retail and access to preventive care services are important measures that cities and communities can take to prevent colon cancer.For more information about the Community Health Profiles Data Initiative, please see the initiative homepage.

BackgroundThere are limited colonoscopy-based cohort data concerning the effectiveness of colonoscopy in reducing colorectal cancer deaths. The aim of this study was to clarify whether colonoscopy reduces colorectal cancer mortality.MethodsA cohort of 18,816 patients who underwent colonoscopy without a diagnosis of colorectal cancer between 2001 and 2010 at high colonoscopy procedure volume centers was selected. Patient characteristics and colonoscopy findings were assessed. The main endpoint was colorectal cancer death (all, right-sided, and left-sided cancers), and data were censored at the time of the final visit or the final colonoscopy. The standardized all colorectal, colon, and rectal cancer mortality rates were estimated with reference to those of the general Japanese population. Additional outcome was all- cause death and the standardized all-cause mortality rate was also estimated.ResultsThe total observed person-year mortality for colorectal cancer was 67,119. Of these, 4, 3, and 1 patients died from colorectal, colon, and rectal cancers, respectively; these values were significantly lower than the number of expected deaths in the general population, estimated to be 53.1, 34.0, and 19.1, respectively. The standardized mortalities for all colorectal, colon, and rectal cancers were 0.08 (95% confidence interval (CI), 0.02–0.17), 0.09 (95% CI, 0.02–0.22), and 0.05 (95% CI, 0.0002–0.21), respectively. There were 586 all-cause deaths (3.11%) during the observation period. The standardized all-cause mortality ratios were 0.22 (95% CI, 0.206–0.23).ConclusionsThe colorectal cancer mortality of patients who received colonoscopy without colorectal cancer diagnosis decreased significantly compared with that of individuals in the general population. These results were compatible even in patients with right-sided colon cancer.

1Hazard Ratio (HR) and 95% Confidence Intervals (CI) adjusted for age, study center, race/ethnicity, sex, AJCC stage, and tumor molecular phenotype: MSI, CIMP, KRAS, and TP53. PARTP based on 10,000 permutations.Genes and related SNPs associated with colorectal cancer-specific mortality among patients diagnosed with colon cancer (gene PARTP≤0.05; SNP Ptrend≤0.10).

Factors associated with colorectal cancer mortality (N = 18,816).

Mortality from colorectal cancer (ICD-10 C17-C21 equivalent to ICD-9 152-154). To reduce deaths from colorectal cancer. Legacy unique identifier: P00225

In 2018, Hungary reported ***** new colorectal cancer cases per 100,000 population, the highest incidence in Europe. This was followed by an incidence rate of **** colorectal cancer cases in Portugal. While in Denmark, **** colorectal cancer cases per 100,000 inhabitants were diagnosed in that year.

Colorectal Cancer Diagnostics Market Outlook

The global colorectal cancer diagnostics market size was valued at approximately $15 billion in 2023 and is projected to reach around $25 billion by 2032, reflecting a compound annual growth rate (CAGR) of 5.5% over the forecast period. One of the primary growth factors driving this market is the rising prevalence of colorectal cancer worldwide, which underscores the urgent need for effective diagnostic solutions.

The increase in colorectal cancer cases can be attributed to several factors including aging populations, lifestyle choices, and genetic predispositions. The aging population is a significant driver, as the risk of colorectal cancer increases with age. With the global demographic shift towards older age groups, there is a heightened need for diagnostic tools that can accurately detect early-stage colorectal cancer. Moreover, sedentary lifestyles, poor dietary habits, and increased consumption of processed foods have all been linked to higher incidence rates of colorectal cancer, further fueling demand for diagnostic tests.

Another critical growth factor is technological advancement in diagnostic methodologies. Innovations such as liquid biopsy, advanced imaging techniques, and AI-based diagnostic tools are enhancing the accuracy and efficiency of colorectal cancer detection. The integration of AI in diagnostics is particularly noteworthy as it assists in quick and precise analysis of medical imaging, thereby improving early detection rates. These technological strides are not only making diagnostics more reliable but also more accessible, contributing to market growth.

Public awareness and government initiatives are also playing a crucial role. Many countries are implementing national screening programs aimed at early detection of colorectal cancer, which is pivotal for improving survival rates. Public health campaigns and increased awareness among the populace about the importance of regular colorectal cancer screening are driving higher participation rates in diagnostic tests. Government funding and subsidies further support the adoption of these tests, particularly in regions with robust healthcare infrastructures.

The introduction of the Colon Cancer Rapid Test Kit is a significant advancement in the field of colorectal cancer diagnostics. This innovative test kit offers a quick and non-invasive method for detecting early signs of colon cancer, making it an attractive option for both patients and healthcare providers. The rapid test kit is designed to provide accurate results within a short time frame, facilitating timely diagnosis and intervention. Its ease of use and accessibility make it particularly suitable for large-scale screening programs, especially in regions with limited healthcare resources. As awareness about the importance of early detection grows, the Colon Cancer Rapid Test Kit is expected to play a pivotal role in reducing colorectal cancer mortality rates.

Regional outlook indicates that North America and Europe currently dominate the colorectal cancer diagnostics market, primarily due to advanced healthcare systems and high awareness levels. However, Asia Pacific is emerging as a significant player due to its large population base and increasing healthcare investments. The region is expected to witness the fastest growth over the forecast period, driven by improvements in medical infrastructure and rising awareness about colorectal cancer.

Test Type Analysis

The colorectal cancer diagnostics market is segmented by various test types, including stool-based tests, imaging tests, biopsy, blood-based tests, and others. Stool-based tests, such as fecal immunochemical tests (FIT) and fecal occult blood tests (FOBT), are widely used for initial screening. These tests are non-invasive and cost-effective, making them popular among patients and healthcare providers. Their simplicity and ease of use make them a staple in early detection strategies, particularly in large-scale screening programs.

Imaging tests, including colonoscopy, CT colonography, and MRI, play a crucial role in confirming diagnosis and staging the disease. Colonoscopy remains the gold standard for colorectal cancer diagnosis due to its high sensitivity and ability to remove polyps during the procedure. Advances in imaging technology have led to improved resolution and reduced patient discomfort, thereby encouraging more people to undergo these tests. CT colonogra

This dataset contains real-world information about colorectal cancer cases from different countries. It includes patient demographics, lifestyle risks, medical history, cancer stage, treatment types, survival chances, and healthcare costs. The dataset follows global trends in colorectal cancer incidence, mortality, and prevention.

Use this dataset to build models for cancer prediction, survival analysis, healthcare cost estimation, and disease risk factors.

Dataset Structure Each row represents an individual case, and the columns include:

Patient_ID (Unique identifier) Country (Based on incidence distribution) Age (Following colorectal cancer age trends) Gender (M/F, considering men have 30-40% higher risk) Cancer_Stage (Localized, Regional, Metastatic) Tumor_Size_mm (Randomized within medical limits) Family_History (Yes/No) Smoking_History (Yes/No) Alcohol_Consumption (Yes/No) Obesity_BMI (Normal/Overweight/Obese) Diet_Risk (Low/Moderate/High) Physical_Activity (Low/Moderate/High) Diabetes (Yes/No) Inflammatory_Bowel_Disease (Yes/No) Genetic_Mutation (Yes/No) Screening_History (Regular/Irregular/Never) Early_Detection (Yes/No) Treatment_Type (Surgery/Chemotherapy/Radiotherapy/Combination) Survival_5_years (Yes/No) Mortality (Yes/No) Healthcare_Costs (Country-dependent, $25K-$100K+) Incidence_Rate_per_100K (Country-level prevalence) Mortality_Rate_per_100K (Country-level mortality) Urban_or_Rural (Urban/Rural) Economic_Classification (Developed/Developing) Healthcare_Access (Low/Moderate/High) Insurance_Status (Insured/Uninsured) Survival_Prediction (Yes/No, based on factors)

Some racial and ethnic categories are suppressed for privacy and to avoid misleading estimates when the relative standard error exceeds 30% or the unweighted sample size is less than 50 respondents. Margins of error are estimated at the 90% confidence level.

Data Source: Centers for Disease Control and Prevention (CDC). Behavioral Risk Factor Surveillance System Survey (BRFSS) Data

Why This Matters

Colorectal cancer is the third leading cause of cancer death in the U.S. for men and women. Although colorectal cancer is most common among people aged 65 to 74, there has been an increase in incidences among people aged 40 to 49.

Nationally, Black people are disproportionately likely to both have colorectal cancer and die from it. Hispanic residents, and especially those with limited English proficiency, report having the lowest rate of colorectal cancer screenings.

Racial disparities in education, poverty, health insurance coverage, and English language proficiency are all factors that contribute to racial gaps in receiving colorectal cancer screenings. Increased colorectal cancer screening utilization has been shown to nearly erase the racial disparities in the death rate of colorectal cancer.

The District Response

The Colorectal Cancer Control Program (DC3C) aims to reduce colon cancer incidence and mortality by increasing colorectal cancer screening rates among District residents.

DC Health’s Cancer and Chronic Disease Prevention Bureau works with healthcare providers to improve the use of preventative health services and provide colorectal cancer screening services.

DC Health maintains the District of Columbia Cancer Registry (DCCR) to track cancer incidences, examine environmental substances that cause cancer, and identify differences in cancer incidences by age, gender, race, and geographical location.

This publication reports on newly diagnosed cancers registered in England during 2022. It includes this summary report showing key findings, spreadsheet tables with more detailed estimates, and a methodology document. Cancer registration estimates are provided for: • Incidence of cancer using groupings that incorporate both the location and type of cancer by combinations of gender, age, deprivation, and stage at diagnosis (where appropriate) for England, former Government office regions, Cancer alliances and Integrated care boards • Incidence and mortality (using ICD-10 3-digit codes) by gender and age group for England, former Government office regions, Cancer alliances and Integrated care boards This publication will report on 2022 cancer registrations only, trends will not be reported as the required re-stated populations for 2012 to 2020 are not expected to be published by the Office of National Statistics (ONS) until Winter 2024.

Legacy unique identifier: P00225

Baseline characteristics of the patients (N = 18,816).

1Hazard Ratio (HR) and 95% Confidence Intervals (CI) adjusted for age, study center, race/ethnicity, sex, AJCC stage, and tumor molecular phenotype: CIMP, KRAS, and TP53. PARTP based on 10,000 permutations.Genes and related SNPs associated with colorectal cancer-specific mortality among patients diagnosed with rectal cancer (gene PARTP≤0.05; SNP Ptrend≤0.10).

Legacy unique identifier: P00226

Deaths from colorectal cancer - Directly age-Standardised Rates (DSR) per 100,000 population Source: Office for National Statistics (ONS) Publisher: Information Centre (IC) - Clinical and Health Outcomes Knowledge Base Geographies: Local Authority District (LAD), Government Office Region (GOR), National, Primary Care Trust (PCT), Strategic Health Authority (SHA) Geographic coverage: England Time coverage: 2005-07, 2007 Type of data: Administrative data

Colorectal cancer is the third most common cancer diagnosed and third leading cause of cancer-related deaths in the United States for both men and women. The American Cancer Society (ACS) estimates about 108,070 new cases of colon cancer and 40,740 new cases of rectal cancer will be diagnosed, and about 49,960 deaths will occur as a result of this devastating disease in 2008. Over the last 20 years, the death rate for this cancer has been dropping as a result of screening and early detection of cancer. In 2007, ACS reported that early-stage colorectal cancer had a survival rate close to 80%, and up to 9,632 deaths could be prevented each year if eligible patients received screening when necessary. However, despite the proven efficacy of colorectal cancer (CRC) screening, only about 50% of eligible US patients are currently being screened. Specific Aims The central hypothesis of this proposal is that patient-initiated prompting of primary care physicians of the patient’s interest in screening will increase referrals for CRC screening. The following three areas will be investigated during this research: 1. To determine whether a communication tool provided to patients will initiate a conversation with their primary care physicians about CRC screening, especially via colonoscopy. 2. To determine whether this tool will impact referral patterns for screening, especially, although not primarily, among poor and underserved populations. 3. To determine whether differences exist in regard to patient-physician communication patterns about screening among residents and faculties in the fields of internal medicine and family practice clinics. At the close of the investigators study, the investigators wish to organize quantifiable data demonstrating how patient-initiated prompting of primary care physicians for CRC screening increases early detection and decreases potential mortality from colorectal cancer. This data will inform a second, larger study to pursue the questions surrounding patient-initiated prompting in

Number and rate of new cancer cases diagnosed annually from 1992 to the most recent diagnosis year available. Included are all invasive cancers and in situ bladder cancer with cases defined using the Surveillance, Epidemiology and End Results (SEER) Groups for Primary Site based on the World Health Organization International Classification of Diseases for Oncology, Third Edition (ICD-O-3). Random rounding of case counts to the nearest multiple of 5 is used to prevent inappropriate disclosure of health-related information.

Non Invasive Colon Cancer Screening Market Outlook

The global non-invasive colon cancer screening market size was valued at approximately USD 1.2 billion in 2023 and is projected to reach around USD 3.5 billion by 2032, growing at a compound annual growth rate (CAGR) of 12.5% during the forecast period. This growth is driven by advancements in screening technology, rising awareness about early cancer detection, and increasing prevalence of colon cancer worldwide.

One of the primary growth factors for the non-invasive colon cancer screening market is the increasing incidence of colorectal cancer globally. Colorectal cancer stands as one of the most common types of cancer, affecting both men and women. The rising awareness about the importance of early detection and the potential to save lives is pushing the demand for non-invasive screening methods. Traditional colonoscopy, although effective, is often avoided by patients due to its invasive nature and associated discomfort, leading to a growing preference for non-invasive methods.

Technological advancements in screening methods are also contributing significantly to the market growth. Innovations such as highly sensitive stool-based tests, blood-based biomarkers, and advanced imaging techniques are providing accurate and reliable alternatives to traditional methods. These advancements are not only improving the detection rates but also enhancing patient compliance due to their non-invasive nature. Moreover, the integration of artificial intelligence and machine learning in diagnostic tools is further refining the accuracy and efficiency of these screenings.

In addition to colorectal cancer, anal cancer is another significant concern that shares some risk factors and screening challenges. The increasing prevalence of both anal and colorectal cancer highlights the need for comprehensive screening strategies that can effectively detect these conditions at an early stage. While colorectal cancer screening has seen significant advancements, anal cancer often remains underdiagnosed due to a lack of awareness and screening protocols. Addressing this gap requires a concerted effort to educate both healthcare providers and the public about the importance of screening for anal cancer, alongside colorectal cancer, to improve outcomes and reduce mortality rates.

Governments and healthcare organizations worldwide are playing a crucial role in promoting non-invasive colon cancer screening. Various awareness programs and initiatives aimed at encouraging regular screenings are being implemented. In addition, favorable reimbursement policies in developed regions are making these screenings more accessible to the general population. These collective efforts are significantly driving the market growth, as early detection is key to reducing the mortality rate associated with colorectal cancer.

From a regional perspective, North America holds the largest share of the non-invasive colon cancer screening market, followed by Europe and Asia Pacific. The high prevalence of colorectal cancer, advanced healthcare infrastructure, and supportive government policies in North America are key factors driving the market in this region. Europe also shows significant growth potential due to increasing awareness and healthcare expenditure. Meanwhile, the Asia Pacific region is expected to witness the fastest growth during the forecast period, owing to the rising healthcare investments, improving diagnostic facilities, and growing awareness about cancer screening in emerging economies.

Test Type Analysis

The non-invasive colon cancer screening market is segmented by test types into stool-based tests, blood-based tests, and imaging tests. Stool-based tests, such as fecal immunochemical test (FIT) and stool DNA test, are gaining popularity due to their ease of use and high sensitivity. These tests are non-invasive, cost-effective, and can be conducted at home, which significantly improves patient compliance. The adoption of stool-based tests is driven by their ability to detect hidden blood in the stool, which is an early indicator of colorectal cancer. Furthermore, advancements in stool DNA tests are enhancing their accuracy and reliability, making them a preferred choice for early detection.

Blood-based tests are another significant segment in the non-invasive colon cancer screening market. These tests detect specific biomarkers associated with colorectal cancer in the blood, offering